Consensus development and application of ICD-9-CM codes for defining chronic illnesses and their complications

Ariel Linden, Thomas J. Biuso, Gopal Allada, Alan Barker, Joaquin Cigarroa, Sai Praveen Haranath, Diana Rinkevich, Karl Stajduhar

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: One particularly difficult challenge in evaluating disease management (DM) programs is defining the scope of economic outcomes to include in the evaluation. Measuring 'all-cause utilization' or 'total costs' assumes that a DM intervention impacts the entire spectrum of services rendered and reduces total medical costs, while limiting the evaluation to 'disease-specific' costs of the conditions under management may fail to capture any effect the program may have on complications directly related to that primary condition. An acceptable compromise between the two options is to include costs associated with diagnostic codes for the primary condition and those of medical complications directly related to that condition. Objective: To develop consensus on the International Classification of Diseases, ninth revision, Clinical Modification (ICD-9-CM) codes defining the primary conditions and complications of coronary artery disease (CAD), congestive heart failure (CHF), asthma, and chronic obstructive pulmonary disease. Methods: A modified Delphi technique, involving two panels of three physicians each (one consisting of cardiologists and the other of pulmonologists) and a physician consultant, was conducted via email and used to establish 100% consensus on the ICD-9-CM codes to be included in order to capture the appropriate costs for each of the primary conditions considered and their complications. The codes for primary conditions included by the panel were compared with those included in industry references. Results: Total consensus on the codes to be included for each of the primary conditions was reached within three rounds. Near-consensus on the codes to be used for complications for conditions was reached after the first round; however, four additional rounds were required for total consensus. Regarding the primary conditions, greatest agreement between the codes included by the panel and the various industry references was seen for asthma, with poor agreement observed between sources of codes for CAD and CHF. Conclusion: It is suggested that these lists of ICD-9-CM codes developed by consensus be used in evaluations across the industry to define the utilization and/or costs associated with DM interventions. The consistent use of these codes will greatly strengthen the validity of the current evaluation approach and consequently substantiate the value proposition offered by the industry.

Original languageEnglish (US)
Pages (from-to)315-322
Number of pages8
JournalDisease Management and Health Outcomes
Volume15
Issue number5
StatePublished - 2007

Fingerprint

International Classification of Diseases
Consensus
Chronic Disease
Industry
Costs and Cost Analysis
Disease Management
Coronary Artery Disease
Asthma
Heart Failure
Delphi Technique
Physicians
Cost of Illness
Consultants
Chronic Obstructive Pulmonary Disease
Economics

Keywords

  • Asthma, assessment
  • Chronic obstructive pulmonary disease, assessment
  • Congestive heart failure, assessment
  • Coronary artery disease, assessment
  • Cost analysis

ASJC Scopus subject areas

  • Health Policy
  • Nursing(all)

Cite this

Consensus development and application of ICD-9-CM codes for defining chronic illnesses and their complications. / Linden, Ariel; Biuso, Thomas J.; Allada, Gopal; Barker, Alan; Cigarroa, Joaquin; Haranath, Sai Praveen; Rinkevich, Diana; Stajduhar, Karl.

In: Disease Management and Health Outcomes, Vol. 15, No. 5, 2007, p. 315-322.

Research output: Contribution to journalArticle

@article{69f793e508e747eeb74a6948f0035513,
title = "Consensus development and application of ICD-9-CM codes for defining chronic illnesses and their complications",
abstract = "Background: One particularly difficult challenge in evaluating disease management (DM) programs is defining the scope of economic outcomes to include in the evaluation. Measuring 'all-cause utilization' or 'total costs' assumes that a DM intervention impacts the entire spectrum of services rendered and reduces total medical costs, while limiting the evaluation to 'disease-specific' costs of the conditions under management may fail to capture any effect the program may have on complications directly related to that primary condition. An acceptable compromise between the two options is to include costs associated with diagnostic codes for the primary condition and those of medical complications directly related to that condition. Objective: To develop consensus on the International Classification of Diseases, ninth revision, Clinical Modification (ICD-9-CM) codes defining the primary conditions and complications of coronary artery disease (CAD), congestive heart failure (CHF), asthma, and chronic obstructive pulmonary disease. Methods: A modified Delphi technique, involving two panels of three physicians each (one consisting of cardiologists and the other of pulmonologists) and a physician consultant, was conducted via email and used to establish 100{\%} consensus on the ICD-9-CM codes to be included in order to capture the appropriate costs for each of the primary conditions considered and their complications. The codes for primary conditions included by the panel were compared with those included in industry references. Results: Total consensus on the codes to be included for each of the primary conditions was reached within three rounds. Near-consensus on the codes to be used for complications for conditions was reached after the first round; however, four additional rounds were required for total consensus. Regarding the primary conditions, greatest agreement between the codes included by the panel and the various industry references was seen for asthma, with poor agreement observed between sources of codes for CAD and CHF. Conclusion: It is suggested that these lists of ICD-9-CM codes developed by consensus be used in evaluations across the industry to define the utilization and/or costs associated with DM interventions. The consistent use of these codes will greatly strengthen the validity of the current evaluation approach and consequently substantiate the value proposition offered by the industry.",
keywords = "Asthma, assessment, Chronic obstructive pulmonary disease, assessment, Congestive heart failure, assessment, Coronary artery disease, assessment, Cost analysis",
author = "Ariel Linden and Biuso, {Thomas J.} and Gopal Allada and Alan Barker and Joaquin Cigarroa and Haranath, {Sai Praveen} and Diana Rinkevich and Karl Stajduhar",
year = "2007",
language = "English (US)",
volume = "15",
pages = "315--322",
journal = "Disease Management and Health Outcomes",
issn = "1173-8790",
publisher = "Adis International Ltd",
number = "5",

}

TY - JOUR

T1 - Consensus development and application of ICD-9-CM codes for defining chronic illnesses and their complications

AU - Linden, Ariel

AU - Biuso, Thomas J.

AU - Allada, Gopal

AU - Barker, Alan

AU - Cigarroa, Joaquin

AU - Haranath, Sai Praveen

AU - Rinkevich, Diana

AU - Stajduhar, Karl

PY - 2007

Y1 - 2007

N2 - Background: One particularly difficult challenge in evaluating disease management (DM) programs is defining the scope of economic outcomes to include in the evaluation. Measuring 'all-cause utilization' or 'total costs' assumes that a DM intervention impacts the entire spectrum of services rendered and reduces total medical costs, while limiting the evaluation to 'disease-specific' costs of the conditions under management may fail to capture any effect the program may have on complications directly related to that primary condition. An acceptable compromise between the two options is to include costs associated with diagnostic codes for the primary condition and those of medical complications directly related to that condition. Objective: To develop consensus on the International Classification of Diseases, ninth revision, Clinical Modification (ICD-9-CM) codes defining the primary conditions and complications of coronary artery disease (CAD), congestive heart failure (CHF), asthma, and chronic obstructive pulmonary disease. Methods: A modified Delphi technique, involving two panels of three physicians each (one consisting of cardiologists and the other of pulmonologists) and a physician consultant, was conducted via email and used to establish 100% consensus on the ICD-9-CM codes to be included in order to capture the appropriate costs for each of the primary conditions considered and their complications. The codes for primary conditions included by the panel were compared with those included in industry references. Results: Total consensus on the codes to be included for each of the primary conditions was reached within three rounds. Near-consensus on the codes to be used for complications for conditions was reached after the first round; however, four additional rounds were required for total consensus. Regarding the primary conditions, greatest agreement between the codes included by the panel and the various industry references was seen for asthma, with poor agreement observed between sources of codes for CAD and CHF. Conclusion: It is suggested that these lists of ICD-9-CM codes developed by consensus be used in evaluations across the industry to define the utilization and/or costs associated with DM interventions. The consistent use of these codes will greatly strengthen the validity of the current evaluation approach and consequently substantiate the value proposition offered by the industry.

AB - Background: One particularly difficult challenge in evaluating disease management (DM) programs is defining the scope of economic outcomes to include in the evaluation. Measuring 'all-cause utilization' or 'total costs' assumes that a DM intervention impacts the entire spectrum of services rendered and reduces total medical costs, while limiting the evaluation to 'disease-specific' costs of the conditions under management may fail to capture any effect the program may have on complications directly related to that primary condition. An acceptable compromise between the two options is to include costs associated with diagnostic codes for the primary condition and those of medical complications directly related to that condition. Objective: To develop consensus on the International Classification of Diseases, ninth revision, Clinical Modification (ICD-9-CM) codes defining the primary conditions and complications of coronary artery disease (CAD), congestive heart failure (CHF), asthma, and chronic obstructive pulmonary disease. Methods: A modified Delphi technique, involving two panels of three physicians each (one consisting of cardiologists and the other of pulmonologists) and a physician consultant, was conducted via email and used to establish 100% consensus on the ICD-9-CM codes to be included in order to capture the appropriate costs for each of the primary conditions considered and their complications. The codes for primary conditions included by the panel were compared with those included in industry references. Results: Total consensus on the codes to be included for each of the primary conditions was reached within three rounds. Near-consensus on the codes to be used for complications for conditions was reached after the first round; however, four additional rounds were required for total consensus. Regarding the primary conditions, greatest agreement between the codes included by the panel and the various industry references was seen for asthma, with poor agreement observed between sources of codes for CAD and CHF. Conclusion: It is suggested that these lists of ICD-9-CM codes developed by consensus be used in evaluations across the industry to define the utilization and/or costs associated with DM interventions. The consistent use of these codes will greatly strengthen the validity of the current evaluation approach and consequently substantiate the value proposition offered by the industry.

KW - Asthma, assessment

KW - Chronic obstructive pulmonary disease, assessment

KW - Congestive heart failure, assessment

KW - Coronary artery disease, assessment

KW - Cost analysis

UR - http://www.scopus.com/inward/record.url?scp=35348850363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348850363&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:35348850363

VL - 15

SP - 315

EP - 322

JO - Disease Management and Health Outcomes

JF - Disease Management and Health Outcomes

SN - 1173-8790

IS - 5

ER -